AstraZeneca reported third-quarter profit after tax of $3.12 billion, up 23 percent, as cancer treatments carried the quarter. Revenue grew 7 percent to $16.2 billion. Core earnings per share, which leave out items such as restructuring costs and the amortisation of acquired drugs, rose 17 percent to $2.79. Profit growth in the previous quarter had been just over 2 percent.
Oncology is the biggest business, at 48 percent of revenue, and its sales rose 17 percent to $7.8 billion. The lung cancer drug Tagrisso and the immunotherapy Imfinzi led the gain.
The savings plan
The company announced a programme called Reshaping for Sustainable Growth, which aims to save $1.5 billion a year and reinvest most of it in its pipeline of more than 180 projects. One-off restructuring charges could reach $2 billion, and the plan is due to be largely finished by the end of 2029. The restructuring could mean job cuts, but none have been announced.
Older drugs under pressure
Sales of Farxiga, used for diabetes, heart and kidney disease, fell 25 percent to $1.6 billion after cheaper US generics arrived. The blood thinner Brilinta has also lost patent protection. In China the company faces a state bulk-buying scheme that trades large orders for price cuts.
Outlook
AstraZeneca confirmed its 2026 guidance, excluding currency effects, of mid-to-high single-digit revenue growth and low double-digit growth in core earnings per share. It also kept its 2030 target of $80 billion in annual revenue, against almost $59 billion in 2025, with about half expected to come from the United States. The company listed its shares directly in New York in February and has pledged $15 billion of investment in China by 2030. It has reported 12 positive late-stage trial results this year and is developing a weight-loss treatment to compete with Wegovy and Mounjaro.
Chief executive Pascal Soriot said the company is on track to deliver its 2030 ambition. Shares rose more than 4.5 percent in early trading on Friday. The next signal will be how the savings plan affects staffing and which pipeline projects absorb the money.





